“What’s in it for the CDMO? That’s the crucial question. We’re not buying a service; we’re establishing a partnership. There has to be interest for both partners.” says Eduardo da Fonseca.

Eduardo da Fonseca, Head of Supply Chain at Bioeq, brings over five years of experience in building a virtual manufacturing operation from scratch. With a background in global companies like Nestlé, Roche, and Acino, Eduardo now leads Bioeq’s innovative approach to supply chain management.

Bioeq is a new Biosimilars company with a clear vision focused on launching specific products in key markets, utilising an out-licensing strategy for commercial distribution and an outsourcing strategy for manufacturing and supply.

In the latest PharmaSource podcast episode, Eduardo explains how he’s built up their value chain from raw materials to delivery of finished products, building a network of external partners and internal teams, to get them to where they are now.

Read the full interview on PharmaSource

--- Learn the essentials of successful biopharma outsourcing.

Outsourcing Fundamentals is a new eLearning course that consolidates best practices from 100+ expert interviews into 10 engaging modules.

Podcast subscribers can use the discount code POD100 to get money off. Sign up here

“Sustainability is not just a trend; it’s integral to our DNA,” says Teva’s Global Head of Sustainability

Amalia Adler-Waxman, SVP, Global Head of Sustainability and ESG and head of Corporate Affairs of International Markets at Teva Pharmaceuticals Industries, brings a wealth of experience from her roles in government, international affairs organisations, and the pharmaceutical industry. Her unique perspective bridges the gap between public and private sectors, offering invaluable insights into the evolving landscape of corporate sustainability.

Amalia Adler-Waxman’s journey with Teva began in 2016 as a consultant. Since then, she has led the company’s transformation into one of the ‘World’s Most Sustainable Companies’, as recognised by Time magazine.

In the latest PharmaSource podcast episode, Amalia explains how Teva’s commitment to sustainability has become a key strategy for driving positive impact and improving business performance.

UniD Manufacturing are the first global Contract Development and Manufacturing Organization (CDMO) fully dedicated to micro-implants based on sustained release and polymeric formulations.

2024 is an important year for UniD Manufacturing, their first as a CDMO open to external customers, with new projects expected to be launched by the year’s end.

Ahead of CDMO Live 2024, Chief Operational Officer Pascal Bertholet shares the company’s innovative strides in micro-implant technology and their vision for a sustainable future.

“2024 marks a significant year for us as we undergo a substantial shift in our business approach.” says Pascal. The company was originally established to develop ocular implants for sister company, EyeD Pharma, but has recently expanded to offer small implants in other therapeutic areas.

“What sets us apart is our expertise in developing both the formulation and the manufacturing process for micro-implants that release active ingredients according to a specific dissolution profile. This can range from a few hours to several years. Our formulations include biodegradable, non-biodegradable, and resorbable polymers,” explains Pascal.

Read the full article on PharmaSource

Prasfarma is a company full of experts in the manufacturing of cytostatic and highly potent products (HPAPI), with a focus on oncology.   

Ahead of CDMO Live we spoke to Diana Alarcón, Business Development Manager at Prasfarma to understand more about the services they offer by the Barcelona-based Contract Development & Manufacturing organisation, and how they have become Annex-1 ready . 

“Prasfarma has made significant investments adapting their facilities and machinery to Annex 1 requirements for the manufacturing of sterile projects. We have expanded our facilities and increased both production and analytical departments.”

Prasfarma has a reputation for working under an agile strategy. We consider our clients as our partners.

“One of our main value is our flexibility. We work on tailor-made projects and we adapted to our customer’s needs” says Diana. 

Read about their upcoming roundtable on Annex 1 here

Vitema is a fast-growing Contract Development and Manufacturing Organization (CDMO) based in Sibiu, Romania.

With one of the largest GMP-certified pharmaceutical manufacturing facilities in Europe, new management team and assets worth over €100 million, they have ambitious goals.

Ahead of CDMO Live we spoke to Diana Serban, the Head of Commercial and Business Development at Vitema.

Diana describes the company as “More than just a CDMO: we are a robust ecosystem that supports the entire pharmaceutical development lifecycle.” This includes everything from the research and development of medicines and food supplements to full-scale production. Vitema also boasts specialised capabilities for oncology products and clinical trials.

Vitema has more than 20 years experience in the pharmaceuticals market, and prides itself on its ability to assist pharmaceutical, biotech, and healthcare companies in delivering high-quality medicines and food supplements to their customers. They offer integrated services, full transparency throughout the entire manufacturing process, and highly competitive pricing data.

Read the full article

Aizon is on a mission to integrate modern computing into the complex arena of GMP manufacturing processes in life sciences.

In the latest episode of the PharmaSource podcast we sat down with Claus Abildgren, Chief Revenue Officer at Aizon, and David O’Gara, Strategic Advisor to Aizon to understand how artificial intelligence can make an impact on manufacturing in the highly-regulated industry.

“Our goal is to evolve the industry by taking pragmatic steps towards enhancing manufacturing performance through practical applications.” says Claus. “We aim to optimize the current capacity of manufacturers and utilize artificial intelligence to anticipate and mitigate the risk of adverse events with predictive capabilities.”

When producing drug products under stringent GMP conditions, “ensuring quality is fundamental. This includes securing data integrity and maintaining comprehensive audit trails—key aspects of deploying technology in a highly regulated environment.”

Leveraging the data generated at a plant leads to identifying opportunities for yield improvements, thereby ensuring high-quality production, delivered on time and at reasonable costs. says David.

“Automated quality reports can significantly reduce the workload for quality organizations and production plant chemists.”

Deploying this technology, especially at CDMOs and for their sponsors, can yield substantial returns, particularly with high-value molecules where even a 1% improvement can have a remarkable impact on return on investment.

Read the full article

“The biggest challenge for scientists to understand that it’s not just your expertise that people are buying, it’s your ability to connect with their problem.” 

Dr. Jeff Kiplinger, a former scientific leader at Pfizer, founded, scaled and sold Averica Discovery Services, a Boston-based CRO specializing in early-stage contract research and analytical development.

Now best-selling of author “Expert to Entrepreneur” and consultant, his company Selling Science advises contract service providers on how to improve their science selling techniques.

Ahead of his lighting talk at CDMO Live, we sat down with Jeff to discuss how CROs and CMOs can position themselves for success in today’s crowded marketplace, and advice for outsourcing leaders in selecting the right partner for their business.

Pfizer CentreOne is an “altogether different kind of CDMO”. Unlike a pure play contract development and manufacturing partner, they don’t own their own plants and pharmaceutical development centres. Instead their customers can leverage the wealth of expertise and state-of-the-art facilities Pfizer possesses.

Ahead of CDMO Live 2024 we sat down with Tom Wilson, VP of Global Contract Manufacturing at Pfizer CentreOne, to discuss how their integrated business model sets them apart from other contract manufacturing partners.

Pfizer CentreOne offers a comprehensive range of services including small molecule API, solid oral dose, sterile injectables, biologics, and cell & gene therapies.

“Pfizer spends over a billion dollars every year to maintain our global network of 38 plants.” says Tom.

“When we bring a client partner on board, they get access to the same manufacturing work centres, scientists, and analysts that Pfizer uses for its products. We have robust ways of controlling intellectual property, ensuring we’re protecting our clients and our own IP.”

“Pfizer’s main mission statement is ‘time is life’. We bring that patient centricity to our CDMO practice. Clients are usually surprised that we’re not talking immediately about our technology, but instead about their patient’s journey, then how can we help make a difference.”

Read the full article

“Good quality supplier data is the backbone of procurement,” says Lana Radosevic,  Global Supplier Lead in Procurement Excellence at Astellas

In her role in Procurement Excellence, Lana Radosevic’s primary focus is on improving supplier data quality across all SaaS systems used by Global Procurement and integrating supplier data. 

In the latest episode of the PharmaSource podcast she explains the importance of accurate supplier data and  shares her experience in driving improvements.

Read the full article on PharmaSource

Terumo is a mid to large size-global medical device company based in Japan, with offices in over 160 countries around the world and over 50,000 products and services.

The Terumo Pharmaceutical Solutions Division, also known as ‘PSD’, is a leading manufacturer of injectable solutions – including primary container, infusion therapy devices, general drug delivery devices – and contract development manufacturing (CDMO) services for parenteral drugs.

“2024 so far has been very good for us.” says Marco Chiadò Piat, President of Terumo Pharmaceutical Solutions Division.

“We’re seeing continuous growth this year, as we did in 2023 and 2022. Continuous growth in capabilities, the solutions we provide to our pharmaceutical customers, and hence a continued increase of the positive impact that we have on patients worldwide.”

Ahead of CDMO Live, we sat down with Marco and Anil Busimi, Vice President Strategy & Marketing at Terumo Pharmaceutical Solutions Division, to discuss the integrated CDMO services that Terumo offer to their growing, international customer base

Read the full article

Grand River Aseptic Manufacturing (GRAM), as the name suggests, is a leading sterile injectable drug manufacturer based in Grand Rapids, Michigan. Following significant investments in state-of-the-art facilities and equipment, GRAM has capacity for fill-finish biologics, small molecules, and vaccines.

Ahead of CDMO Live, we had the opportunity to sit down with David Powell, Vice President of Business Development at GRAM.

“We strive to have the latest manufacturing technology. All our equipment is always cutting-edge. But at the same time, as a good old Mid-west company, customer focus, authenticity, and transparency are the hallmarks of who we are.” say David

During the COVID-19 pandemic, GRAM helped manufacture the vaccine. “We pivoted and quickly invested in more capacity. Now, post-COVID, we have a significant amount of capacity available to our customers, with a total of three fill lines and a fourth on the way,” David explained.

With newer capabilities and facilities, GRAM has pivoted to specialize in biologics fill-finish.

“That is where our sweet spot is. We’re not into drug substance, we’re not in oral solids, we are really just focused on fill-finish and helping our customers, large or small, take their products through and get it to market.”

GRAM have announced plans for a third manufacturing facility focused on syringe and cartridge filling to complement existing capabilities.

“We’re leaving plenty of space to also get into more downstream auto injector and other device manufacturers assembly for our syringe and cartridge customers. We realize we need to continue to expand in there to match the market demand.”

• Read the full article on PharmaSource

Bayer Consumer Health heavily relies on contract development and manufacturing, maintaining a network of nearly 200 contract manufacturers that account for approximately half of their global sales.

This is set to change with the Project Martini initiative, which aims to significantly “shake up” and consolidate their network of contract manufacturers.

Speaking ahead of CDMO Live, David Buhmann, Vice President of Procurement Finished Goods, explains the new strategy and its critical importance to Bayer.  

“Contract Manufacturers are an integral part of our overall supply chain. We require top-tier partners to ensure that we fulfil our mission of helping over 1 billion people lead healthier lives with the most trusted selfcare solutions in the market. This includes every link in the supply chain, including the CMO network.”

Over the years, Bayer’s contract manufacturing network has grown organically, resulting in a situation where the company now collaborates with nearly 200 CMO sites, accounting for roughly half of the company’s revenue.

“Our priorities shifted rapidly during the COVID-19 pandemic,” says David. “Initially, our focus was on securing materials and supplies at any cost. However, more recently, we’ve shifted our attention to cost management and cash flow, right-sizing the inventories that accumulated during the pandemic.”

Read the full article on PharmaSource

“Building mutual understanding and trust is the foundation for optimising performance and driving innovation with contract manufacturing organisations (CMOs),” says Guosheng Zhao, Senior External Manufacturing Lead at LEO Pharma.

Guosheng Zhao brings years of experience in procurement, management consulting at PWC, and working with contract manufacturers at companies such as Procter and Gamble and Philips to his role.

At LEO Pharma, Guosheng is responsible for external manufacturing of dermatology and thrombosis medicines, a portfolio spanning both small molecules and biologics, with a focus on maintaining stable product supply and quality across complex global supply chains.

In the latest PharmaSource podcast episode, Guosheng explains why effective supplier relationship management is crucial for reducing costs, improving margins, and ensuring consistent medicine supply for patients.

Read the full article on PharmaSource

Onyx Scientific is a Contract Development and Manufacturing Organization (CDMO) that specializes in process R&D, non-GMP scale-up, and GMP manufacture for clinical trials and commercial applications.

With facilities in the UK and US, their dedicated teams in chemistry, solid-state and analytical chemistry guide small molecule Active Pharmaceutical Ingredient (API) products through development and manufacturing.

In anticipation of CDMO Live, we had a conversation with Chris Atherton, the Commercial Manager of Onyx Scientific, who shed light on their business operations.

"Onyx was one of the first chemistry CDMOs to invest in solid-state, and we plan to continue investing in this area in the future." says Chris.

Established in 2000, Onyx Scientific has garnered 24 years of successful experience within the preclinical development space, completing thousands of development projects. Their pragmatic ‘fit for purpose’ approach is centred on intelligent rapid process development with an eye towards future GMP campaigns.

Connect with Onyx Scientific at CDMO Live

“Contract negotiations are often perceived as a POWER GAME but in reality, it has to be a collaboration.” says Dr Roxana Timmermans

In the latest episode of the PharmaSource podcast, Dr. Timmermans explains why contract negotiations are of critical importance in pharma outsourcing and shares her framework for success.

“Proper negotiation, is the foundation of a strong partnership. In the highly regulated world of pharma contract manufacturing, precise terms are essential."

"Negotiation skills are not just desirable; they are paramount, says Roxana. “If you not trained you will put the company in a very damaging position.”

Read the interview The Art of Contract Negotiations

While pharmaceutical companies have proven the return on investing in digital at early stages of drug discovery, manufacturing has been slower to embrace digital transformation.

To understand how pharma R&D and manufacturing can unlock more business value through adopting digital tools and technologies, we speak to Digital CMC consultant Mark Buswell.

Mark is a chemical engineer by training, with over 20 years in R&D and Manufacturing at GSK, before joining NGT BioPharma consultants to head up Digital CMC services to help pharmaceutical companies navigate digital transformation of their CMC function.

Read the full article on Digital CMC Maturity on PharmaSource

In 2024 the world of Contract Development & Manufacturing has been going through a period of major upheaval.

Since the start of the year, every day have been significant acquisitions or investments in the CDMO space. In the United States there are highly significant legislative changes working their way through Congress which will re-define the industry.

Ahead of his talk at CDMO Live, we spoke Gil Roth, President and founder of the PBOA (Pharma & Biopharma Outsourcing Association) to give us his take on all the challenges and opportunities faced by this dynamic sector.

• For more insights into the changing contract manufacturing landscape in the United States, don’t miss Gil’s expert talk at CDMO Live in June, where he will be sharing his insights on How the upcoming US Election and Legislative Changes could Impact CDMOs. Register here for your free ticket

Alcami, a contract development and manufacturing organization headquartered in North Carolina, is in a period of high growth.

With more than 50 years of experience advancing products through every stage of the development lifecycle, Alcami serves pharmaceutical and biotech companies of all sizes for small molecules and biologics – primarily in the United States.

Ahead of CDMO Live, we sat down with Kerrie Powell, Senior Vice President of Sales at Alcami Corporation, to understand more about the services that the company offers to clients, and how they help clients to navigate the the fast-changing contract manufacturing landscape in 2024.

Register today for your free ticket

Supplier Relationship Management is a ‘systematic approach to evaluating vendors that supply goods, materials, and services to an organization. It involves determining each supplier’s contribution to success and developing strategies to improve their performance’.

Anirban Mukherjee, Head of Procurement at Immunovant, argues that while Supplier Relationship Management (SRM) is crucial for achieving high performance in complex industries such as pharma and biotech, it often receives insufficient attention.

In the latest episode of the PharmaSource podcast, Anirban explains the steps to take when implementing a successful SRM programme, drawing on his experience at Ford, Becton Dickinson, and Gilead, where he served as the Global Head of Development for outsourced vendor management.

Anirban is passionate about SRM in driving business outcomes: “Over the course of your career, you realize what you deeply believe in” he says.

Read the full article here

On International Women's Day 2024, the PharmaSource community hosted an important debate, asking "how can the biopharma industry do better at supporting and elevating women into leadership roles?"

The panel included Elke Geysen, SVP Head of Global Procurement and External Supply at Grünenthal Group, Roxana Timmermans PhD, Supply Chain Procurement & Global Alliances Leader and was chaired by Alicia Ryan, Principal Consultant at Proxima.

Read the full Women in Pharma article on PharmaSource

In today’s episode we talk about real-world applications of AI and Pharma 4.0 and how it can make a difference to Pharma Manufacturing.

Our guest is Daniel O’Mahoney a Digital Transformation consultant in the Life Sciences, working for Körber Pharma, and Part-time Lecturer in Pharma 4.0 Bio-Industry 4.0 NIBRT National Institute for Bioprocessing Research and Training

In this interview, we talk about how to get started with Pharma 4.0, a concept that applies the principles of Industry 4.0 to the pharma sector, and some of the ways that technology can be used to improve the productivity of pharmaceutical manufacturing.

Read the full interview on PharmaSource

“Honesty is between sponsor and contract manufacturer is essential,” says Philip Coetzee, Director CMO Management for Daiichi Sankyo Europe.

“Be honest. I find it very difficult to work with someone who tells me ‘half-truths and whole lies’. I’d rather someone say – ‘someone messed up’ than try to hide it. It’s human. Things happen.”

In the latest episode of PharmaSource podcast Philip talks about his experience on both sides of the table - from his experience working at Catalent and now leading contract manufacturing outsourcing Daiichi Sankyo Europe

Successful partnerships thrive on trust, transparency, and genuine connections. Here are some key takeaways from Philip’s insights on optimising relationships with Contract Manufacturing Organizations:

• Build Personal Connections: Philip emphasizes the value of one-to-one relationships with key account managers. Getting to know them personally fosters better collaboration and understanding.

• Smaller CMOs can be more rewarding: Philip finds working with smaller CMOs more rewarding. It allows him to connect with key personnel, including CEOs, on a personal level.

• Appropriate Honesty: Philip advocates for sharing relevant information with CMOs. Explain why their quote wasn’t accepted, and provide constructive feedback. More information is better than too little.

Read https://pharmasource.global/content/dos-and-donts-of-managing-contract-manufacturers-interview-with-philip-coetzee-daiichi-sankyo/https://pharmasource.global/content/dos-and-donts-of-managing-contract-manufacturers-interview-with-philip-coetzee-daiichi-sankyo/

DON’T MISS!

Philip will be hosting a roundtable at #CDMOLive on the topic of how to run better RFP/RFQs. To join the session, sign up here

Bernardo Estupiñán has a career spanning chemistry and business development, and now working as a consultant to guide companies developing new biopharmaceuticals through contract manufacturing

In this interview we talk about his advice for how biotechs can successfully navigate the contract manufacturing landscape in order to bring new products into the clinic on budget.

“The biggest challenge? Money. “ says Bernardo.

Key considerations for Biotech contract manufacturing 1. Manufacturing Location Matters

2. Standardise processes to reduce costs

3. Find the right size and cultural fit

4. Document everything for a Smooth Tech Transfer

Read the full article How to navigate contract manufacturing in biotech

“Supply chain leaders make things work. They get things done, but they don’t shine,” says Knut Alicke, McKinsey Partner and co-author of ‘From Source to Sold‘. 

‘From Source to Sold’ contains a series of interviews with top Supply Chain leaders, showcasing the stories of their journeys to leadership positions. Knut’s research revealed that only 11% of CEOs in the Fortune 200 had a supply chain background, highlighting the untapped potential for supply chain professionals to reach top executive positions.

• For more book recommendations, checkout the PharmaSource Book Club

In the latest episode of the PharmaSource podcast, Knut explains why recognising and developing supply chain leadership is crucial for driving strategic growth and innovation in corporates.

He explains that the ‘CHAIN’ model was developed from the interviews. It is a framework for professionals looking to enhance their supply chain management skills and advance their careers.

Read the full interview on PharmaSource

“Sustainability is giving more than you take.”

Fred Turco is Vice President of Enterprise Indirects and Sustainable Sourcing Lead at Pfizer.

In the latest episode of the PharmaSource podcast he explains how the company is making progress towards its targets by collaborating with suppliers.

The Enterprise Indirects team Fred manages operates across 85 countries and 300 facilities managing the majority of indirect spend, and play a key role in driving the sustainability agenda for the company.

Speaking to the PharmaSource podcast he shares his advice for how to be a successful procurement business partner and how Pfizer are making real-world progress towards a more sustainable business.

Read the full article here

“Small to midsize biotechs are the future of the biopharma industry” says Stefan Verhayden, Global Vice President of GX biological solutions and syringes at Gerresheimer. Stefan leads the company’s packaging and drug delivery services in the fast growing biopharma segment.

“They are the ones develop molecules that then afterwards, either go commercial to themselves or are being picked up by the bigger biopharma companies that then will bring them to a commercial phase.”

In the latest episode of the PharmaSource podcast, he explains some of the challenges biopharma customers face, such as personalised medication.

Read the full article

AlfaSigma, the Italian pharmaceutical company, has undergone significant changes with three acquisitions in the last 12 months.

At the same time Fabio Russo, who recently joined as the Chief Procurement Officer, is pioneering a transformation of the procurement function.

Leveraging his background in management consulting, he is introducing a new target operating model that repositions the procurement function as a strategic business enabler to support the company’s growth.

“Consulting is very much about delivering concepts and designs. I missed rolling up my sleeves and going into execution mode. I’ve joined AlfaSigma at a very exciting time,” he says.

In the latest episode of the PharmaSource podcast, Fabio breaks down his strategy, the digital journey that the team is embarking on, and how to stay aligned with the needs of an evolving business.

Read the full story on PharmaSource

Grifols Partnership, is a contract development and manufacturer (CDMO) focused on added-value injectable products for small molecules, headquartered in Barcelona, Spain.

In this episode of the PharmaSource podcast, Marga Viñes Senior Business Development Manager for Grifols contract manufacturing, explains the drug development and manufacturing services that they offer to customers.

“Grifols is mainly known in the blood-derivatives field.” says Marga. 

Additionally the company’s “contract manufacturing experience in injectable drugs led to us offering CDMO services focusing on Orphan drugs. We are very specialised in small-volume parenteral manufacturing.”

Read more on PharmaSource

Negotiating for yourself can be challenging. If you are a woman there are still implicit biases you might face, and self-doubt that can undermine your confidence and performance. Yet, knowing your worth and negotiating for it is crucial for advancing your career, increasing your income, and achieving your goals.

In the latest Women in Pharma Procurement meetup, our expert panel shared best practices for how to negotiate for yourself effectively, overcome common barriers, and close the gender pay gap.

Why it matters:

• Continuing gender pay gap: In 2021, women earned only 83% of what men earned in full-time wage and salary roles. After an MBA, the gap widened to 63% ten years later.
• The long game matters: A small difference in starting salary can have a huge impact on your wealth over time. For example, if you get a $100,000 salary and your co-worker negotiates up to $107,000, you would have to work eight years longer to be as wealthy as them at retirement.

Read the full article

Clinical research is a vital part of developing new treatments and cures for diseases. But it is also a complex and challenging process that faces many obstacles and inefficiencies.

Scott Schliebner is a Clinical Development Executive and advisor to early-stage biotech companies, helping them to design and execute clinical trials.

In the latest episode of the PharmaSource podcast, he shares his insights on some of the current problems and opportunities in clinical research, and how biopharmas can navigate the complex CRO industry in 2024.

Read the full interview here

Malik Akhtar is Vice President at Bayer Consumer Health Division, where he oversees a network of 5000 suppliers, including direct materials, APIs, and 180 contract manufacturers.

Speaking on the PharmaSource Podcast, Malik explains the “Three C” procurement strategy which defines the areas of greatest focus for Bayer in 2024 and beyond:

• Cost Containment
• Cash-Flow improvement
• CO2 De-carbonisation

Read the interview here:

“We want to be the leader in decarbonisation of the glass industry.” says Olivier Rousseau, Chief Executive Officer of SGD Pharma.

SGD Pharma is a worldwide manufacturer of molded and tubular glass for pharmaceutical primary packaging, producing 8 million vials and bottles per day.

In the latest episode of the PharmaSource podcast, Olivier sets out the company's plans for 2024 and explains how the whole company is now lazer-focused on being the most sustainable in the industry.

“2024 will be a full year of innovation” says Olivier. “We are on a growth path” with new partnerships and facilities being announced to join its existing global infrastructure of five ISO 15378 certified GMP compliant manufacturing plants.

SGD Pharma's Decarbonisation Strategy

Decarbonisation is now the company's top priority, explains Olivier.

"Our goal is to clearly lead the pharmaceutical glass primary packaging industry. We truly believe that more drug manufacturers will look to carbon levels and sustainability strategies to choose their suppliers."

"We had the ambition of reducing our CO2 emissions by 35% by 2021, and now we are working towards reducing them by 65% by 2040." he says.

“We are investing significantly in the decarbonisation of all our industrial processes and working with customers and partners across the full value chain to uncover scope one, scope two and scope three emissions to get to our goal."

Some of the decarbonisation initiatives for SGD Pharma include:

1. Hybrid furnaces

2. Re-designing industrial processes

3. Collaborating on lighter products

4. Working across the full value chain

Read the full article

“Biology is the most complex system in the known universe." says Markus Gershater, Chief Scientific Officer and Cofounder, Synthace. "The fundamental problem we're trying to solve is to how to experiment with something as complex as biology.“

In a recent survey conducted by the digital experimentation platform, 87% of scientists said their greatest challenge “keeping track of all the different elements involved” with experimentation.

Synthace’s mission is to help scientists to navigate and unpick complexity, helping them to understand what’s going on with their experiments and ultimately discover better therapeutics and biological solutions.

Read the full article on PharmaSource

BD Medical - Pharmaceutical Systems provides a broad range of parenteral drug delivery systems including glass and plastic pre-fillable syringes, safety and shielding systems as well as advanced drug delivery solutions that help ensure pharma meets its drug delivery goals.

An this interview with Dragana Cvijanovic, Business Director, Processability & Sustainability and Marie-Liesse Le Corfec, Business Head of B2B Medication Delivery Solutions, BD (Beckton Dickinson) we discuss BD's patient-centred innovations and why the industry must do more to achieve sustainability targets.

Read more How Realistic are Pharma’s De-Carbonisation Targets?

“The best CDMO is the one you haven’t worked with.” says Audrey Greenberg.”That’s really unfortunate.. it’s not that hard to be a good service provider.”

Audrey is the Founder of Centre for Breakthrough Medicines, the innovative, Pennsylvania-based Cell & Gene therapy Contract Development and Manufacturing Organization (CDMO).

Audrey launched and then sold the company to SK Pharmteco, where she is currently is Chief Business Officer for their wider CDMO business that operates facilities in United States, Ireland, France, and South Korea.

In the latest episode of PharmaSource podcast Audrey discusses her journey in launching a CDMO that put digital at the centre of operations right from the start.

“Digital infrastructure is an important piece that people underestimate.” say Audrey.

Read the full interview

In an uncertain world rife with cost inflation, the pharmaceutical industry is seeking innovative solutions. René Wienmann, Chief Procurement Officer at Chr. Hansen, is leading the charge with data-driven procurement insights that are driving savings and sustainability.

René, who proudly identifies as a “procurement nerd or geek,” is leveraging technology to navigate the increasing complexity of procurement in a volatile, uncertain, complex, and ambiguous (VUCA) world.

In the latest episode of the PharmaSource podcast, René elaborates on his data-driven CPO procurement strategy. Read the full article

What is the best way to make progress towards pharma’s net zero targets? “Get started,” says Chris Shanahan, VP Global Sustainability Supply Chain at Thermo Fisher Scientific.

“Starting can be intimidating and overwhelming. There’s a lot going on, and we don’t always have all the information. But if everyone gets started, we will eventually come together. Don’t put it off.”

Chris Shanahan leads Sustainability efforts for the Thermo Fisher supply chain, following a career in life science procurement at GSK (then Haleon), BD, before joining Thermo Fisher Scientific where he spent the last 17 years as a CPO.

Chris explains why he transitioned from a procurement lead to a sustainability lead. “It’s really about creating something for the future for my own children. Climate change and unusual weather events are here and when you think about the impact we can make on supply chains, we are in a position to influence this and make things happen.”

“Climate-related issues, water waste, human rights, or ensuring fairness for workers in the workplace, these are all topics that are rapidly changing and evolving. In the last 12-18 months, I have seen a lot of change in terms of what expectations are, regulation in Europe and the US, and investors are asking about what companies are doing across sustainability ESG.”

“The way I think about my role is getting things done: executing and pulling through the commitments that companies make. That’s what we’re doing at Thermo Fisher.”

Ambition and Realism

While disruptive events like the COVID pandemic and global inflation may have changed the ability for companies to invest at a quicker rate, senior leadership at Thermo Fisher Scientific have ring-fenced their commitment to make sure that the investment is still there, says Chris.

Thermo Fisher Scientific’s net zero targets are broken down by scope and near and long-term targets

“Our ambition is net zero by 2050. My role is to say, how do we really make it happen? What are the things we must do?”

“Infrastructure needs to change, behavioural changes need to happen, you need to bring people along. It’s all about aspiration, and how quickly you can push, but also, what’s really logical and rational to get there. Some of this stuff takes time.”

Chris gives the example of sites, in countries and states where the grids and the infrastructure are not ready. “If we set a 2030 goal or 2040 goal, we know it’s not realistic because we’re dependent on so many other factors.”

“The investment cycle might get slightly delayed. Inflation is a pretty significant impact on costs, but it doesn’t take away from the actual commitments for 2030 or 2050.”

“It’s about balancing the portfolio as we go through this period. Most companies will go through this sort of pain and hurt and cycle. As you look over history, inflation happens but good times come back. It’s really about how do you flatline and balance that over periods and when you get the good times, you might need to accelerate the investment.”

Educating colleagues and the industry

Educating colleagues, peers and suppliers is critical if the industry will progress together, says Chris.

“Sustainability is something we all have to get educated on. It impacts everything – how we buy, where we place things. Education on the basics of scope one, scope two and scope three helps people to understand what sustainability really means and how to address the challenges.”

• Register to PharmaSource for more insights

Marketing in pharma can be tough. In the contract manufacturing space where the services of one provider might look very similar to another, it can be a challenge to build a distinctive brand and to target at customers at the right moment in their drug development process.

In the latest episode of the PharmaSource podcast, Elliott Berger – formerly Chief Marketing Officer at Catalent and currently Strategic Advisor for Orientation Marketing and Fractional CMO – shares his insights into how marketing can make a real impact in this industry.

From babies to baby molecules

Elliott has previously held a series of senior positions in J&J Consumer Group of Companies on world famous brands like Johnson’s Baby. “In consumer health we would spend literally hundreds of millions of dollars to experiment and work the best talent, best agencies, the best creatives and the biggest media companies”.

He then applied those lessons to Catalent where he led “one of the most active and aggressive marketing programmes in this industry”.

Elliott found the biggest change in moving into B2B was to “adjust from large, emotional marketing to drive impulse purchases” to targeting a business customer “who are trying to buy complex projects with multiple stakeholders, multiple influencers or large process large spending over a period of time.”

Elliott draws a direct comparison between targeting pregnant women, who are at a clear stage in the baby’s development, and targeting pharmaceutical executives who are nurturing their “baby molecule” through the drug development process.

In this interview he shares the following best practices for marketing that can cut through the noise.

Read the full article

Lonza Capsules and Health Ingredients is the global leader in the capsule manufacturing market, says Julien Lamps, Associate Director of Global Product Management.

Speaking on the PharmaSource podcast, Julien explains how Lonza support the pharmaceutical industry with a range of science-backed capsule innovations.

“We are the most well-known in the market for our Capsugel® brand products” says Julien.

“Our manufacturing footprint is well established. We have 10 manufacturing sites worldwide, in every region of the world, producing 250 billion capsules a year”

This scale means Lonza are able to deliver products worldwide to any pharmaceutical customer regardless of geography or regulatory requirements.

“We are really focused on bringing innovations to the market. We helping our customers find new ways of delivering drugs and enabling people and patients to live a better life”

Along with pharmaceutical business, Lonza have a large customer-base in the nutrition industry where their capsules are used for vitamins and minerals.

Why capsules are the patient-friendly option

The common challenges that pharmaceutical manufacturers face is to “improve the bioavailability of drugs” says Julien. “Making sure that they are delivered with the smallest amount within the body, with efficient and consistent delivery”

“Capsule are by essence the easiest dosage form. They are very convenient to store, to ship and to get into your body in a simple way.”

Julien points out that capsules are a far better patient experience than using syringes and injection, with all the complications this involves for patients and clinics.

Enteric-coated capsules

The biggest products in the Lonza portfolio are capsules that dissolve in the stomach to deliver their contents in either liquid or solid form.

Julien explains that recently they have developed a new range of Capsugel® Enprotect® capsules, which are designed for release in the intestines.

“Capsugel® Enprotect® capsules are our latest innovation in the pharmaceutical space. It is a dual-layer capsule that will withstand the acid media of your stomach and will deliver only once it has reached the small intestine.”

Enteric properties are built in, the capsule eliminates the need for additional enteric manufacturing steps such as adding solvents.

Smart Pills are on the way

Julien confirmed that ‘Smart Pills’ are a key trend he believes will become a mainstream reality in the next five years, with some projects already in progress.

“Smart capsules communicate more information to patients and healthcare professions. They can share information which can help to improve the efficacy of the treatment and ultimately improve patient adherence” he says.

Collaboration with customers

Collaborating with partners is key for Lonza Capsules and Health Ingredients, Julien says.

To help collaborate with customers, Lonza have recently launched the Lonza Capsule Application Lab, a physical facility in France where customers can visit to define their needs, develop projects and launch a proof of concept is done.

His advice is to look for parter with a strong regulatory background, who will help you understand what constraints and opportunities you face in the pharmaceutical industry, and who can prove the performance of their products with data.

“In capsules there are many players, but customers need to ensure they speak to suppliers who are backed up with scientific research” says Julien.

Read more on PharmaSource

Ray Sison is the Managing Partner for SCxCMC, connecting biotech companies with highly qualified CDMOs, strategic consultants and independent contractors.

Changing contract manufacturer is not a decision to be taken lightly, yet can be necessary to take a product to a commercial stage says Ray Sisons.

Ray Sison is the Managing Partner for SCxCMC, a consultant who specialises in connecting biotech companies with highly qualified CDMOs and independent contractors.

In his work with early stage biopharmas, Ray often finds they are managing several contract manufacturers without a formal supply chain strategy or procurement function.

"There's the supply chain you launch with, and then there's the supply chain, you actually will use in day-to-day commercial operations." he says.

"Often when we arrive we find a cobbled together set of Contract Manufacturers (CMOs) that may or may not have had the proper commercial skillset or capacity to meet the long term forecast for the product."

In the latest episode of PharmaSource podcast, Ray Sisons shares his advice on how to manage CMC and Supply Chain partnerships.

Vendor Selection

"From the very beginning, a clear project definition really sets your priorities. You need to know what it is you're trying to outsource, where you are in the business cycle and what's your exit."

"A client that is looking for a 'one stop shop' is very different to a biotech that just needs to get prototypes and preliminary stability work done."

"Bottom line, you need the right voices at the table to set the selection criteria." says Ray.

"It's not just the scientist at the bench that has the final say on who you outsource, you need to talk to your quality, compliance and regulatory. And ,if you have that function set up already, you should be talking to your commercial and supply teams about their objectives."

Ray says it's also important to take into account 'intangible' elements such as corporate culture, leadership quality when selecting a partner.

Deciding when to part company from an existing supplier

"Deciding to cut a CDMO loose may not a comfortable question asked in the presence of a CDMO", say's Ray, but it may be necessary.

"Working with a CDMO is a partnership but it's also a business transaction. If one side fails to deliver, if it does not meet its contractual obligations, timeline or deliverables, then action needs to happen."

Reviewing contractual terms

"We use all the project management and business tools that we have at our disposal before we look at the contract and start taking legal action. If we simply view there should be an exit clause, that's typically where you can get out for cause or without cause."

"The red flag is if one of the sides is no longer negotiating in good faith. If that sounds like a legal term it's because it is. It's the language we use to mean we've got to the place where one or both sides become so frustrated, that they're looking at the language of the contract to see what they're supposed to do next."

"In a functioning relationship, you don't do that - you pick up the phone, you call them and you figure out a way to work it out. But if it’s evident that one of the parties is not acting in good faith, not negotiating that looking to actually solve the problem... that for me is the moment when you decide we need to look elsewhere." says Ray.

Always have a backup

For many smaller companies having more than one CDMO working on a the same product may not be economically viable. However, there is no reason not to have backups on stand-by, says Ray.

"Always have multiples, as part of the vendor selection process. I recommend that you have a primary and you have a backup."

"You negotiate with the primary, obviously, as you want to move forward with them. Make sure to keep a relationship with the backup, even if you don't initially contract with them. That way if things go sideways you have options."

Read the full article on PharmaSource

This episode is a live recording from our first Women in Pharma Procurement meetup.

Pharma is an industry where 90% CEOs are men, and the gender pay gap is still a very real issue. In this session we learned that pay disparity is  no.1 challenge women are facing in their roles.

Since we launched PharmaSource community, it’s been clear that driving a real and meaningful change for women is an area that many of our members are passionate about. 

The panel debate you’re about to hear was chaired by Alicia Ryan, Principal Consultant  Proxima, with Tanya Momtahen,  VP Integrated Product Solutions. Thermo Fisher Scientific, Sharmeen Lalani-Fade, Global Procurement Lead: Online Media & Data, Bayer, along with contributions from members.

To find out more about this session and to get involved in future events, head to /https://pharmasource.global/content/tackling-the-gender-pay-gap-is-the-no-1-challenge-for-women-in-pharma-procurement-video/

1990’s technology stacks will not give us the supply chain that 21st century customers need and deserve, says Elouise Epstein.

Speaking to the PharmaSource podcast, Kearney partner, author and futurist Elouise Epstein explains that “Third-party data exchange is the key to the future. Above all, we need to facilitate easy data exchange with suppliers.”

In her new book, How to Hack the Supply Chain, Elouise describes an experience she had during COVID-19 when was given her vaccination record on a piece of paper. With no digital record, there was no way for her to understand the provenance of the drug she was putting into her body.

“I realised that none of these entities were integrated. There is no data exchange with the third-parties developing and distributing pharmaceuticals.”

This lack of transparency comes with real risk, says Elouise.

“When we extend supply chains we make them brittle and susceptible to risk. Our inability to exchange data has created vulnerability”

Elouise has come to the conclusion that the 21st supply chain technology platform should based around cloud technologies that are able to facilitate data exchange with third-parties, rather than the Enterprise Resource Planning (ERP) systems that currently represent the foundation of most pharma supply chains.

Read the full article on PharmaSource

How should a 100 year-old pharma company partner with a tech giant such as Google?

Sharmeen Lalani-Fade, Global Procurement Lead for online media, creative and data for Bayer explains how they are partnering with Google to bring their Advertising technology (AdTech) stack in house.

The project is designed to connects the 'demand side' (Bayer's marketing campaigns) with the online advertising 'supply side' (websites that show as such as Google, YouTube etc) - without the need of advertising agencies.

"The goal of the project is to be less reliant on agencies and more accountable" says Sharmeen.

“The holy grail of procurement is cost transparency. When you're buying everything through a media agency, however good they are, they're just not built to give you transparency. “

There were challenges with 100 year old company trying to interface with a new breed tech company.

“Not all advertisers directly contract with tech platforms." says Sharmeen "It's a decision that a company can't really take lightly. It requires a great deal of upscaling of the organisation… marketing, procurement, accounts payable all need to go on the digital journey together”

As Sharmeen explains, the project "required a great deal of due diligence. You need to be prepared for some of the common pitfalls".

7 takeaways from the Bayer / Google partnership for procurement professionals.

1. Aim for a true strategic partnership

2. Educate yourself about the tech landscape

3. Help the supplier to understand your world

4. Ensure contracting processes align

5. Marketing effectiveness has to be measured in-house

6. With great data ownership comes great responsibility

7. Stay strongly aligned with stakeholders

Read the full article here:

Avantor is a Fortune 500 company with a wide range of mission-critical products and services for the biopharma industry.

David Coorey, SVP Biopharma Business Development & Commercial Operations at Avantor spoke to the PharmaSource podcast to explain more about the services they offer.

David explains how Avantor supports biopharma companies through R&D scientific discovery, to scale up and full commercial GMP manufacturing materials including custom use excipients and single use consumables.

“Avantor’s has evolved a unique ‘systems approach’ to designing full Fluid handling solutions for customers” says David. “We work with customers to design and optimise a solution that’s tailored to their unique manufacturing process” rather than a rigid, one-size-fits-all approach.

Avantor operates in more than 30 countries, with 14,500 globally. In addition Avantor’s channel brand, VWR offers an integrated, seamless purchasing experience that is optimised for the way our customers do business.

Read the full article here

Brian Whitlock, Vice President of Global R&D Procurement at Bristol Myers Squibb shares his experience in building a high-performance operating model to support the business objectives of biopharmaceutical research.

In the latest episode of the PharmaSource podcast Brian explains how the procurement operating model had to change following 2019, when BMS announced the acquisition of Celgene.

“The acquisition was a sea change for how we think about procurement, and how to support a much larger critical R&D business unit with 9,000 scientists worldwide.” he says.

Procurement had to align with the priorities for the wider Bristol Myers Squibb business: building a world class pipeline, improving productivity and reducing development cycle times while also delivering high quality medicines to our patients.

In order for procurement to support this, Brian explains that “There has been a lot of process reengineering, both internally and with our partners, but also tapping capabilities that exist within the supplier market, that perhaps we have not made a direct investment in.”

Brian worked with leaders within R&D function to design an operating model that “not only focuses on driving the high volume, high risk and high visibility opportunities but also have individuals with unique skill sets that can drive an innovation portfolio.”

“Procurement played a very important role sitting at the table with our stakeholders to bring those new capabilities to our enterprise.”

“One of the things I absolutely love about R&D is we have very creative scientists that come up with challenging opportunities. Every day is different. Every challenge is a little bit unique. It’s that variation, and the complexity of these challenges that really motivate us day to day.”

The conversation covers the follows:

• Strategic procurement helps navigate challenging times
• Cultivate an innovation mindset to increase speed to market
• Re-designing procurement for speed
• Deep accountability for your category
• Innovation comes from smaller transactions
• One team, serving Patients
• BMS Prime: Enabling self service
• The growing importance of Computer Aided Research
• How important is having a scientific background?

Full article here

“CDMO environments can often be very tough and chaotic, requiring leaders who can navigate uncertainty" says Neil Kelly, CEO and founder of Vector, a company specializing in talent solutions for the biopharma industry. 

"To succeed in this sector, you need to be able to thrive in 'grey' areas. Not all leaders can handle this kind of environment."

At CDMO Live 2024, a poll of attendees indicated that leadership skills was the most significant talent-related issue that was holding their company back from achieving growth.

“Strong leadership is critical in any organization, but it's especially vital in the fast-paced and complex world of CDMOs." says Neil, speaking on the PharmaSource podcast.

Read the full interview

Asymchem is a large USFDA-inspected Contract Development and Manufacturing Organization (CDMO), renowned for its expertise in developing sustainable processes for late-phase to commercial small molecule and peptide Active Pharmaceutical Ingredients (APIs).

The contract manufacturer has eight manufacturing facilities spread across China, and delivers “500-600 projects a year, with 50 assets available for western markets,” says Jon Brice, Senior Vice President of Business Development at Asymchem Group.

In this interview with the PharmaSource podcast, Jon explains that what makes Asymchem unique is their two flagship technologies:

• Flow chemistry, where Asymchem is “arguably the world leader” in pharmaceutically-relevant flow chemistry.
• Biocatalysis, reactions catalysed by enzymes which are much less toxic than methods using metals.

“If you look at the suite of technology we’ve developed, it’s a toolbox you can’t find at any other CDMO,” Jon adds.

Sustainability has become the key focus for the entire pharma industry, according to Jon.

“We interact with 18 of the top 20 market cap pharma companies in the world, and the one topic that comes up at every meeting is sustainability. It’s really started to accelerate over the last 9-12 months.”

Five years ago, sustainability was more of an aspiration. Now, it’s a legitimate interest with real progress being made. Companies are now required to prove their commitment to sustainability, with each having their own scorecard and tracking metrics.

Asymchem’s flagship technologies position them perfectly to deliver value against these sustainability goals.

“1 in 2 projects we do uses a biocatalytic step with an Asymchem enzyme,” Jon explains. Biocatalysts (sometimes called nature’s catalysts) provides a legitimate avenue of progress in making processes greener.

“Flow processes are inherently less polluting as they allow for the recirculation of reactive streams on a small amount of solvent, using less polluting materials. These processes are inherently de-risked, leading to fewer accidents, less flammable material, and less risk of running foul of environmental agencies.

Last year, Asymchem were awarded the inaugural ACS Award for CMO Excellence in Green Chemistry for leveraging innovative manufacturing technologies to deliver sustainable processes.

“The client wanted us to change their existing manufacturing processes to flow chemistry.” says Jon. ” It was their insistence and their driving criteria for vendor selection move away from waste-producing methods and to do this in sustainable way.”

Read full interview

Skyepharma is a fully-integrated CDMO specialised in formulating, developing and producing complex oral dosage forms and expanding into Bioproduction with the opening of their new SkyeHub plant.

Based outside Lyon, France, the company offers their worldwide customer base a full range of services, from early stage development to industrial manufacturing and packaging.

Following a management buyout in 2021, SkyePharma is now fully owned by its management team.

In the latest episode of the PharmaSource podcast Skyepharma CEO David Lescuyer and Chief Business Officer Laurent Rigaudeau discuss the transformation journey the company is on.

“The management buyout allowed us to continue on our growth path as an independent French company.” says David.

“Now when a client meets the management team, they also meet the owners of Skyepharma. We are truly committed to the projects of our clients”.

A significant milestone for the CDMO is the recent completition of Skyehub, their new bioproduction plant, developed in partnership with MaaT Pharma.

“Skyehub was answer to something that was missing in the market.” says David, explaining how they have been working with MaaT Pharma since 2018 and together conceived a facility that could finalise the development of their product under GMP conditions for commercial use.

The plant is owned by SkyePharma, and available for other companies from early 2024.

“We had to build a brand new biotech plant with clean rooms inside, ready to build to the latest genomes. We had to implement the right quality system that allows them to produce under GMP conditions, and it all had to be delivered in in 13 months.”

Hitting these goals “was a huge challenge” says David, but the project was delivered on time and to budget.

In addition, over the last two years Skyepharma have adapted their facility to the production of Highly potent APIs (HPAPI), says Laurent.

“We have built a dedicated building for research and development of HPAPIs.  The next exciting project for us is to launch a fully dedicated new area to expand our services into more complex molecules and oncological products.”

Read the full article: https://pharmasource.global/content/supplier-spotlight/skyepharma-independent-french-pdmo-expands-to-hpapis-and-bio/

World Courier, a specialist in logistics, warehousing, and transportation services for the pharma and biopharma industry, covers the entire supply chain from preclinical stages and universities to commercial products.

With 50 years of experience in the storage and transportation of time and temperature-sensitive products, World Courier is part of the Cencora group (formerly AmerisourceBergen), allowing it to tap into a wider range of services.

Alan Runacus, UK Sales Manager, explains how World Courier supports pharma and biotechs of all sizes to access important markets.

“World Courier is not just about delivering packages; we ensure that products and samples get to where they need to be at the correct time and temperature for quality.”

As an example, World Courier holds licenses in all 52 states in America, facilitating storage and distribution.

“This makes it easier for European organizations trying to launch in the US or small Biotechs who simply don’t have the scale to apply for them all individually. World Courier can take that on and distribute direct to pharmacies.”

World Courier has been delivering direct-to-patients for over 20 years and today has a dedicated global team for personalised supply chains.

“The market has evolved significantly in recent years” says Alan. “Our network now includes more cryogenic stations around the world. We use liquid nitrogen shippers, the mode of choice for Cell & Gene therapies.”

“We were the first to introduce GPS in all our multi-use packaging systems. Clients can click into an online portal to see where their package is. “

“These therapies have made everybody look at packaging solutions to deliver safety and integrity of the product because it’s going back to a patient. “

Read the full article

SUANFARMA provides Contract Development and Manufacturing (CDMO) services for fermentation and chemical synthesis projects – both generic and innovator.

The company offers a ‘One Stop Shop’ service helping customers to achieve success in the development, scaling, manufacturing, and commercialization of APIs.

David Blanco Industrial Business Development & CDMO Director, explains the services that they offer to customers.

“SUANFARMA is more than just a CDMO, we are a real strategic partner for success in achieving customers’ final goals. We have a flexible mindset and full transparency with customers, providing them with tailored solutions to meet specific needs.”

“We specialise helping pharmaceutical, biotech and healthcare companies by delivering fully integrated services that compress timelines to market. We provide global solutions that enable customers to achieve their objectives with high quality at affordable cost, including full regulatory support for FDA and EMA.”

The pharma industry needs CDMO partners to be flexible with manufacturing due to changing market dynamics, says David.

“Our flexibility and transparency are highly valued by our customers, we adapt to changes that arise during the project accommodate, batch size requirements and guarantee the capacity on time as per the business plan.”

David explains that a key differentiator for SUANFARMA is offering a single European manufacturing plant can combine GMP, industrial processes of fermentation, purification and chemical synthesis services.

“Centralisation of commercial manufacturing processes at a single site simplifies the supply chain and thus achieves highly attractive costs, minimises risk and optimises time.”

The sustainability footprint is also improved as the site including access for full waste recycling, use of green power, and the use of green chemistry to reduce environmentally harmful processes.

Innovative solution for wastewater treatment

SUANFARMA’s ground-breaking Pharmaceutical Wastewater Treatment Project has led to them being nominated alongside their partner e-Watts have been nominated for the 2023 CPHI Awards in the Sustainability category.

“It’s the world’s first large scale installation that treats industrial volumes with a flow rate of up to 250 m3 per hour.” says David.

“Our innovative solution is an improvement of existing wastewater treatment technologies that often rely on dangerous chemicals or incineration, which can be harmful to the environment.”

“We use electro-oxidation which doesn’t require the use of dangerous chemicals and can remove non-biodegradable compounds and pollutants from volumes of wastewater, making it a much more efficient and eco friendly option.”

In addition, the plant generates green hydrogen as a by-product of the electrolysis process, which can be used as an energy source to reduce the facility’s dependency on external energy sources.

Read the full article here